Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Filings indexed 678 across all filing types
Latest filing 2026-03-02 Regulatory Filings
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
8-K - PROTAGENIC THERAPEUTICS, INC.\NEW (0001022899) (Filer)
Regulatory Filings
2026-03-02 English
8-K - PROTAGENIC THERAPEUTICS, INC.\NEW (0001022899) (Filer)
Regulatory Filings
2026-02-24 English
25-NSE Filing
Delisting Announcement
2026-01-23 English
8-K Filing
Regulatory Filings
2026-01-05 English
DEF 14A
Proxy Solicitation & Information Statement
2025-12-05 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.